|
US6743777B1
(en)
*
|
1992-03-19 |
2004-06-01 |
Eli Lilly And Company |
Cyclic peptide antifungal agents and process for preparation thereof
|
|
US6582728B1
(en)
|
1992-07-08 |
2003-06-24 |
Inhale Therapeutic Systems, Inc. |
Spray drying of macromolecules to produce inhaleable dry powders
|
|
US6051256A
(en)
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
|
ATE264096T1
(de)
|
1994-03-07 |
2004-04-15 |
Nektar Therapeutics |
Verfahren und mittel zur verabreichung von insulin über die lunge
|
|
GB9501841D0
(en)
*
|
1995-01-31 |
1995-03-22 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
|
GB9515182D0
(en)
*
|
1995-07-24 |
1995-09-20 |
Co Ordinated Drug Dev |
Improvements in and relating to powders for use in dry powder inhalers
|
|
US5871010A
(en)
*
|
1996-06-10 |
1999-02-16 |
Sarnoff Corporation |
Inhaler apparatus with modified surfaces for enhanced release of dry powders
|
|
US7052678B2
(en)
|
1997-09-15 |
2006-05-30 |
Massachusetts Institute Of Technology |
Particles for inhalation having sustained release properties
|
|
US6309623B1
(en)
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
|
US6946117B1
(en)
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
|
US6433040B1
(en)
|
1997-09-29 |
2002-08-13 |
Inhale Therapeutic Systems, Inc. |
Stabilized bioactive preparations and methods of use
|
|
US6956021B1
(en)
|
1998-08-25 |
2005-10-18 |
Advanced Inhalation Research, Inc. |
Stable spray-dried protein formulations
|
|
GB9827145D0
(en)
|
1998-12-09 |
1999-02-03 |
Co Ordinated Drug Dev |
Improvements in or relating to powders
|
|
ATE248187T1
(de)
|
1999-03-03 |
2003-09-15 |
Lilly Co Eli |
Echinocandin-kohlenhydrate-komplexe
|
|
ES2433678T3
(es)
*
|
1999-03-03 |
2013-12-12 |
Eli Lilly & Company |
Formulaciones farmacéuticas de equinocandina que contienen tensioactivos formadores de micelas
|
|
US7252840B1
(en)
|
1999-08-25 |
2007-08-07 |
Advanced Inhalation Research, Inc. |
Use of simple amino acids to form porous particles
|
|
US6586008B1
(en)
|
1999-08-25 |
2003-07-01 |
Advanced Inhalation Research, Inc. |
Use of simple amino acids to form porous particles during spray drying
|
|
CN1188111C
(zh)
|
1999-10-29 |
2005-02-09 |
耐科塔医药公司 |
分散性得到改进的干粉组合物
|
|
EP1129705A1
(en)
|
2000-02-17 |
2001-09-05 |
Rijksuniversiteit te Groningen |
Powder formulation for inhalation
|
|
GB0009469D0
(en)
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
|
PE20011227A1
(es)
|
2000-04-17 |
2002-01-07 |
Chiesi Farma Spa |
Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
|
|
CA2382133C
(en)
|
2000-05-10 |
2010-11-23 |
Alliance Pharmaceutical Corporation |
Phospholipid-based powders for drug delivery
|
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
|
DK1296651T3
(da)
*
|
2000-06-27 |
2008-02-11 |
Vectura Ltd |
Fremgangsmåde til fremstilling af partikler til anvendelse i et farmaceutisk præparat
|
|
EP1296651B2
(en)
|
2000-06-27 |
2019-07-17 |
Vectura Limited |
Method of making particles for use in a pharmaceutical composition
|
|
DK2283818T3
(da)
*
|
2000-11-30 |
2017-10-16 |
Vectura Ltd |
Fremgangsmåde til fremstilling af partikler til anvendelse i en farmaceutisk sammensætning
|
|
EP1337239B2
(en)
|
2000-11-30 |
2015-11-25 |
Vectura Limited |
Particles for use in a pharmaceutical composition
|
|
DK1337240T4
(da)
*
|
2000-11-30 |
2015-01-05 |
Vectura Ltd |
Fremgangsmåde til fremstilling af partikler til brug i en farmaceutisk sammensætning
|
|
US20040052733A1
(en)
*
|
2000-11-30 |
2004-03-18 |
Staniforth John Nicholas |
Pharmaceutical compositions for inhalation
|
|
WO2002054868A2
(en)
*
|
2000-12-21 |
2002-07-18 |
Inhale Therapeutic Syst |
Pulmonary delivery of polyene antifungal agents
|
|
WO2002056948A1
(en)
|
2001-01-17 |
2002-07-25 |
Vectura Limited |
An inhaler device
|
|
US6681768B2
(en)
|
2001-06-22 |
2004-01-27 |
Sofotec Gmbh & Co. Kg |
Powder formulation disintegrating system and method for dry powder inhalers
|
|
WO2003072016A2
(en)
*
|
2001-11-19 |
2003-09-04 |
Becton, Dickinson And Company |
Pharmaceutical compositions in particulate form
|
|
CA2465675C
(en)
|
2001-11-20 |
2008-06-10 |
Advanced Inhalation Research, Inc. |
Improved particulate compositions for pulmonary delivery
|
|
WO2003053411A1
(en)
|
2001-12-19 |
2003-07-03 |
Nektar Therapeutics |
Pulmonary delivery of aminoglycosides
|
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
|
US6991800B2
(en)
|
2002-06-13 |
2006-01-31 |
Vicuron Pharmaceuticals Inc. |
Antifungal parenteral products
|
|
US20040204439A1
(en)
*
|
2003-04-14 |
2004-10-14 |
Staniforth John Nicholas |
Composition, device, and method for treating sexual dysfunction via inhalation
|
|
JP2006522634A
(ja)
*
|
2003-04-14 |
2006-10-05 |
ベクトゥラ・リミテッド |
投与効率を向上させるデバイス及び製薬組成
|
|
CN102688224A
(zh)
*
|
2003-04-14 |
2012-09-26 |
维克特拉有限公司 |
用于提高剂量效率的药物组合物和装置
|
|
US20060147389A1
(en)
*
|
2004-04-14 |
2006-07-06 |
Vectura Ltd. |
Devices and pharmaceutical compositions for enhancing dosing efficiency
|
|
MXPA05012821A
(es)
|
2003-05-28 |
2006-02-13 |
Nektar Therapeutics |
Formulacion farmaceutica que comprende un agente activo insoluble en agua.
|
|
GB0327723D0
(en)
*
|
2003-09-15 |
2003-12-31 |
Vectura Ltd |
Pharmaceutical compositions
|
|
GB0321607D0
(en)
|
2003-09-15 |
2003-10-15 |
Vectura Ltd |
Manufacture of pharmaceutical compositions
|
|
US20060292081A1
(en)
*
|
2003-09-15 |
2006-12-28 |
Vectura Limited |
Methods for preparing pharmaceutical compositions
|
|
GB0326632D0
(en)
|
2003-11-14 |
2003-12-17 |
Jagotec Ag |
Dry powder formulations
|
|
GB0425758D0
(en)
|
2004-11-23 |
2004-12-22 |
Vectura Ltd |
Preparation of pharmaceutical compositions
|
|
GB0426301D0
(en)
*
|
2004-11-30 |
2004-12-29 |
Vectura Ltd |
Pharmaceutical formulations
|
|
US8524735B2
(en)
|
2005-05-18 |
2013-09-03 |
Mpex Pharmaceuticals, Inc. |
Aerosolized fluoroquinolones and uses thereof
|
|
DK1901749T3
(da)
|
2005-05-18 |
2016-10-24 |
Raptor Pharmaceuticals Inc |
Aerosoliserede fluorquinoloner og anvendelser heraf
|
|
GB0525254D0
(en)
*
|
2005-12-12 |
2006-01-18 |
Jagotec Ag |
Powder compositions for inhalation
|
|
US8153604B2
(en)
*
|
2006-04-24 |
2012-04-10 |
Geron Corporation |
CNS-tumor treatment method and composition
|
|
DE102006030164A1
(de)
|
2006-06-29 |
2008-01-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Inhalative Pulver
|
|
US20090048155A1
(en)
|
2007-08-15 |
2009-02-19 |
Endacea, Inc. |
Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
|
|
US9522916B2
(en)
|
2007-12-21 |
2016-12-20 |
Constance Neely Wilson |
A1 adenosine receptor antagonists
|
|
CA2739893C
(en)
|
2008-10-07 |
2016-10-04 |
Mpex Pharmaceuticals, Inc. |
Inhalation of levofloxacin for reducing lung inflammation
|
|
US8815838B2
(en)
|
2008-10-07 |
2014-08-26 |
David C. Griffith |
Aerosol fluoroquinolone formulations for improved pharmacokinetics
|
|
ES2739352T3
(es)
|
2009-02-26 |
2020-01-30 |
Glaxo Group Ltd |
Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
|
|
PT2410981T
(pt)
|
2009-03-26 |
2017-05-25 |
Pulmatrix Inc |
Formulações em pó seco e métodos para tratar doenças pulmonares
|
|
EP3569235A1
(en)
|
2009-09-04 |
2019-11-20 |
Horizon Orphan LLC |
Use of aerosolized levofloxacin for treating cystic fibrosis
|
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
|
GB0921481D0
(en)
|
2009-12-08 |
2010-01-20 |
Vectura Ltd |
Process and product
|
|
WO2011094208A2
(en)
|
2010-01-26 |
2011-08-04 |
Endacea, Inc. |
Methods and pharmaceutical compositions for preventing and treating renal impairment
|
|
US20130164338A1
(en)
|
2010-08-30 |
2013-06-27 |
Pulmatrix, Inc. |
Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
|
|
AU2011296343B2
(en)
|
2010-08-30 |
2015-12-10 |
Pulmatrix Operating Company, Inc. |
Dry powder formulations and methods for treating pulmonary diseases
|
|
CA3086367A1
(en)
|
2010-09-29 |
2012-04-05 |
Pulmatrix Operating Company, Inc. |
Monovalent metal cation dry powders for inhalation
|
|
PT2621488T
(pt)
|
2010-09-29 |
2019-02-12 |
Pulmatrix Operating Co Inc |
Pós secos catiónicos
|
|
TW201304822A
(zh)
|
2010-11-15 |
2013-02-01 |
Vectura Ltd |
組成物及用途
|
|
WO2012073025A1
(en)
|
2010-11-30 |
2012-06-07 |
Vectura Limited |
Glucosaminoglucans such as heparin for use in the treatment of pulmonary inflammation such as copd
|
|
JP6021117B2
(ja)
|
2011-01-31 |
2016-11-02 |
ジェノア ファーマシューティカルズ,インク. |
エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
|
|
US9572774B2
(en)
|
2011-05-19 |
2017-02-21 |
Savara Inc. |
Dry powder vancomycin compositions and associated methods
|
|
DK2739268T3
(da)
|
2011-08-01 |
2019-02-25 |
Univ Monash |
Fremgangsmåde og formulering til inhalation
|
|
CN104487075A
(zh)
|
2012-02-29 |
2015-04-01 |
普马特里克斯公司 |
可吸入干粉剂
|
|
US8993041B2
(en)
|
2012-10-15 |
2015-03-31 |
New Jersey Institute Of Technology |
Taste masked active pharmaceutical powder compositions and processes for making them
|
|
CN104968332B
(zh)
|
2012-11-12 |
2020-10-20 |
新泽西理工学院 |
药用芯-壳复合粉末及其制备方法
|
|
GB201305825D0
(en)
|
2013-03-28 |
2013-05-15 |
Vectura Ltd |
New use
|
|
AU2014248455B2
(en)
|
2013-04-01 |
2018-12-06 |
Pulmatrix Operating Company, Inc. |
Tiotropium dry powders
|
|
US20150044288A1
(en)
|
2013-07-31 |
2015-02-12 |
Windward Pharma, Inc. |
Aerosol tyrosine kinase inhibitor compounds and uses thereof
|
|
EP4491180A1
(en)
|
2014-01-10 |
2025-01-15 |
Avalyn Pharma Inc. |
Aerosol pirfenidone and pyridone analog compounds and uses thereof
|
|
EA201691872A1
(ru)
|
2014-03-19 |
2017-04-28 |
Инфинити Фармасьютикалз, Инк. |
Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
|
|
WO2015179369A1
(en)
|
2014-05-20 |
2015-11-26 |
Infinity Pharmaceuticals, Inc. |
Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors
|
|
WO2016057644A1
(en)
*
|
2014-10-08 |
2016-04-14 |
Pulmatrix Operating Company, Inc. |
Improved stability of dry powders containing tiotropium and amino acid
|
|
CA2965759C
(en)
|
2014-10-31 |
2023-12-12 |
Glaxosmithkline Intellectual Property Development Limited |
Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
|
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
|
EP3340982B1
(en)
|
2015-08-26 |
2021-12-15 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
|
CN108289841A
(zh)
*
|
2015-12-24 |
2018-07-17 |
菲利普莫里斯生产公司 |
带香味尼古丁粉末
|
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
AU2017290593A1
(en)
|
2016-06-27 |
2019-01-03 |
Achillion Pharmaceuticals, Inc. |
Quinazoline and indole compounds to treat medical disorders
|
|
KR102559152B1
(ko)
*
|
2016-06-30 |
2023-07-26 |
필립모리스 프로덕츠 에스.에이. |
니코틴 입자
|
|
US10139321B2
(en)
*
|
2016-07-29 |
2018-11-27 |
Alpha-Tec Systems, Inc. |
Mucolytic tablet for a sample collection device
|
|
CN110603252A
(zh)
|
2017-03-01 |
2019-12-20 |
艾其林医药公司 |
用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
|
|
CN118440096A
(zh)
|
2017-06-20 |
2024-08-06 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
KR20210018199A
(ko)
|
2018-03-26 |
2021-02-17 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스의 분해를 위한 세레블론 결합제
|
|
WO2020041301A1
(en)
|
2018-08-20 |
2020-02-27 |
Achillion Pharmaceuticals, Inc. |
Pharmaceutical compounds for the treatment of complement factor d medical disorders
|
|
WO2020081723A1
(en)
|
2018-10-16 |
2020-04-23 |
Georgia State University Research Foundation, Inc. |
Carbon monoxide prodrugs for the treatment of medical disorders
|
|
KR20210152515A
(ko)
|
2019-04-12 |
2021-12-15 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스 및 아이올로스의 트리시클릭 분해제
|
|
CA3142758A1
(en)
*
|
2019-06-10 |
2020-12-17 |
Respira Therapeutics,Inc. |
Carrier-based formulations and related methods
|
|
WO2021127452A1
(en)
|
2019-12-19 |
2021-06-24 |
Georgia State University Research Foundation, Inc. |
Compounds for the treatment of bacterial infections and potentiation of antibiotics
|
|
US20250197403A1
(en)
|
2020-02-20 |
2025-06-19 |
Achillion Pharmaceuticals, Inc. |
Heteroaryl compounds for treatment of complement factor d mediated disorders
|
|
AU2021231898A1
(en)
|
2020-03-05 |
2022-10-27 |
C4 Therapeutics, Inc. |
Compounds for targeted degradation of BRD9
|
|
CN116437913A
(zh)
|
2020-09-23 |
2023-07-14 |
艾其林医药公司 |
用于治疗补体介导的病症的药物化合物
|
|
WO2022240897A1
(en)
|
2021-05-10 |
2022-11-17 |
Sepelo Therapeutics, Llc |
Pharmaceutical composition comprising delafloxacin for administration into the lung
|
|
WO2023028364A1
(en)
|
2021-08-27 |
2023-03-02 |
Sepelo Therapeutics, Llc |
Targeted compositions and uses therof
|
|
IL321202A
(en)
|
2022-12-02 |
2025-07-01 |
Kinaset Therapeutics Inc |
PAN-JAK inhibitor formulation
|